Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells (original) (raw)
- Original Paper
- Published: 23 January 1998
- Min Kim1 na1,
- Ekta Ohri1,
- Robert Wersto2,
- Dai Katayose1,
- Zhuangwu Li1,
- Yung Hyun Choi1,
- Bali Mudahar1,
- Shiv Srivastava3,
- Prem Seth1 &
- …
- Kenneth Cowan1
Oncogene volume 16, pages 265–272 (1998)Cite this article
- 722 Accesses
- 6 Altmetric
- Metrics details
Abstract
We constructed an adenoviral vector containing human p16 cDNA in order to evaluate the cytotoxic effects of exogenous p16 expression on cancer cell proliferation and to explore the potential use of p16 in cancer gene therapy. Following infection of human breast (MCF-7, MDA-MB-231, and BT549), osteosarcoma (U-2 OS and Saos-2), cervical (C33a), and lung cancer (H358) cell lines with the recombinant adenovirus Adp16, high levels of p16 expression were observed in all cell lines. Cancer cell lines which were mutant or null for p16 but wild-type for the retinoblastoma gene product (pRb) (MCF-7, MDA-MB-231, BT549 and U-2 OS) were 7 – 22-fold more sensitive to the cytotoxic effects of Adp16 than to a control virus. In contrast, cancer cell lines which were wild-type for p16 but mutant or null for pRb (Saos-2, C33a and H358) were <threefold more sensitive to Adp16 when compared to a control virus. Analysis of 5-bromodeoxyuridine incorporation into DNA following infection with Adp16 showed a loss of S phase in those cell lines which were null or mutant for p16 but expressed a functional pRb. This cell cycle arrest was associated with binding of the p16 protein to cyclin-dependent kinase 4 and dephosphorylation of pRb. In contrast, human cancer cell lines expressing a wild-type p16 and a mutant pRb or no pRb showed no substantial loss of S phase following Adp16 infection. Based on these studies, we conclude that p16-mediated cytotoxicity is tightly associated with the presence of functional pRb in human cancer cells, and that tumor cells which are mutant or null for p16 are candidates for Adp16 mediated cancer gene therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Additional access options:
Similar content being viewed by others
Author information
Author notes
- Caroline Craig and Min Kim: CC and MK made equal contribution
Authors and Affiliations
- Medicine Branch, National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland
Caroline Craig, Min Kim, Ekta Ohri, Dai Katayose, Zhuangwu Li, Yung Hyun Choi, Bali Mudahar, Prem Seth & Kenneth Cowan - Pathology Branch, National Cancer Institute, National Institutes of Health, Bethesda, 20892, Maryland
Robert Wersto - Surgery Branch, USUHS, Bethesda, 20814, Maryland, USA
Shiv Srivastava
Authors
- Caroline Craig
You can also search for this author inPubMed Google Scholar - Min Kim
You can also search for this author inPubMed Google Scholar - Ekta Ohri
You can also search for this author inPubMed Google Scholar - Robert Wersto
You can also search for this author inPubMed Google Scholar - Dai Katayose
You can also search for this author inPubMed Google Scholar - Zhuangwu Li
You can also search for this author inPubMed Google Scholar - Yung Hyun Choi
You can also search for this author inPubMed Google Scholar - Bali Mudahar
You can also search for this author inPubMed Google Scholar - Shiv Srivastava
You can also search for this author inPubMed Google Scholar - Prem Seth
You can also search for this author inPubMed Google Scholar - Kenneth Cowan
You can also search for this author inPubMed Google Scholar
Rights and permissions
About this article
Cite this article
Craig, C., Kim, M., Ohri, E. et al. Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells.Oncogene 16, 265–272 (1998). https://doi.org/10.1038/sj.onc.1201493
- Received: 10 March 1997
- Revised: 11 August 1997
- Accepted: 12 August 1997
- Published: 23 January 1998
- Issue Date: 15 January 1998
- DOI: https://doi.org/10.1038/sj.onc.1201493